TCRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer...

Stats
Today's Volume	92 052.00
Average Volume	196 857
Market Cap	319.19M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-0.250 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.42
ATR14	$0.0240 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Baker Bros. Advisors Lp	Buy	8 851 451	Warrants to purchase Common Stock
2024-04-19	Baker Bros. Advisors Lp	Buy	825 968	Warrants to purchase Common Stock
2024-04-19	Lynx1 Capital Management Lp	Buy	5 000 000	Pre-funded Warrant (right to buy)
2024-02-01	Amello Jason	Buy	750 000	Stock Option (Right to Buy)
2024-01-29	Amello Jason	Buy	0

INSIDER POWER
99.17
Last 93 transactions
Buy: 66 481 256 \| Sell: 5 443 695

Volume Correlation

Long: -0.10 (neutral)

Short: -0.69 (moderate negative)

Signal:(43.678) Neutral

TScan Therapeutics, Inc. Correlation

10 Most Positive Correlations
CRSA	0.871
HALL	0.871
MVBF	0.868
SNCR	0.859
OSMT	0.857
MYNA	0.84
SOUN	0.839
KFRC	0.824
LMFA	0.823
LMNL	0.819

10 Most Negative Correlations
SLVO	-0.879
BNIXU	-0.864
BMRN	-0.85
ARTNA	-0.848
MRNA	-0.839
FNKO	-0.838
CAMP	-0.836
FNWD	-0.823
AVDX	-0.815

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TScan Therapeutics, Inc. Correlation - Currency/Commodity

0.20
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.17
( neutral )

-0.10
( neutral )

0.36
( neutral )

TScan Therapeutics, Inc. Financials

Annual	2023
Revenue:	$21.05M
Gross Profit:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2023
Revenue:	$21.05M
Gross Profit:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2022
Revenue:	$13.54M
Gross Profit:	$8.40M (62.05 %)
EPS:	$-2.74

FY	2021
Revenue:	$10.14M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-4.17

Financial Reports:

No articles found.

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.